Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Segment — Intangible asset amortization

Similar metrics at other companies

Synaptics Inc. logo
SYNAReportable Segment — Intangible asset amortization
$21.9M-25.5%
Home Depot logo
HDPrimary Segment — Intangible asset amortization
$52M0.0%
Banc of California logo
BANCIntangible asset amortization
$6.35M-11.3%
Banc of California logo
BANCIntangible asset amortization
$6.35M-11.3%
Home Depot logo
HDOther — Intangible asset amortization
$119M+36.8%
Ingram Micro logo
INGMEMEA — Intangible asset amortization
$6.45M+10.1%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$955.82M-16.0%
Enterprise value$810.41M-19.5%
P/E20×-11.4×
P/S1.2×-0.4×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept coll:AmortizationAndImpairmentOfIntangibleAssets.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Product revenues, net$199,878$188,000$393,398$365,757
Cost of product revenues (excluding intangible asset amortization)26,63324,14347,43449,103
Intangible asset amortization62,95355,473118,426110,946
Commercial expenses46,40344,11593,76084,908
Corporate expenses12,1639,80126,70323,090
Medical expenses7,8997,83215,04715,865
Technical operations expenses165136415234
Stock-based compensation expense14,48410,81825,36422,342

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s segment — intangible asset amortization?
Collegium Pharmaceutical, Inc. (COLL) reported segment — intangible asset amortization of $62.95M in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s segment — intangible asset amortization changed year-over-year?
Collegium Pharmaceutical, Inc.'s segment — intangible asset amortization increased by 13.5% year-over-year, from $55.47M to $62.95M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — intangible asset amortization?
Over 2 years (2022 to 2024), Collegium Pharmaceutical, Inc.'s segment — intangible asset amortization has grown at a 10.1% compound annual growth rate (CAGR), from $136.26M to $165.3M.
What does segment — intangible asset amortization mean?
Reflects the periodic non-cash expense related to the allocation of the cost of acquired intangible assets, such as patents and product rights, over their useful lives. Monitoring this helps investors understand the impact of past acquisitions on current reported earnings.

Ask your AI about Collegium Pharmaceutical, Inc.'s segment — intangible asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude